{"disease":{"id":"fibrodysplasia-ossificans-progressiva-fop","name":"fibrodysplasia ossificans progressiva fop"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06064656","title":"A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)","phase":"","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT05090891","title":"To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT05027802","title":"A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Ipsen","has_results":true},{"nct_id":"NCT07301450","title":"An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)","phase":"","overall_status":"TEMPORARILY_NOT_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}